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Rise in testing and diagnosis associated with Scotland’s Action Plan on Hepatitis 
C and introduction of dried blood spot testing 
 
INTRODUCTION 
An estimated 210,000 people in the UK (0.4% and 0.8% of the adult 
population in England and Scotland, respectively) are chronically infected with the 
hepatitis C virus (HCV); as many as half are undiagnosed.[1] As these individuals 
remain infectious, are at risk of developing liver disease and may not receive 
treatment this is a major issue for the control and management of the epidemic.  
In Scotland, there have been several national initiatives with the aim of 
increasing HCV testing and diagnosis, as summarised in Appendix 1. During the early 
to mid 2000s, the Scottish Needs Assessment Programme report, the Royal College of 
Physicians consensus statement and SIGN guidelines established recommendations 
for testing: people who inject drugs (PWID), organ donors, HIV positive individuals, 
children of HCV positive mothers, sexual and household contacts of cases, and those 
who received dental or medical treatment in high prevalence countries with poor 
infection control.[2- 4] The SIGN guidelines suggested high priority for case finding 
should be given to former PWID, especially those over 40 years, who may have more 
advanced disease and benefit from treatment.  
It was not until the launch of Scotland’s Hepatitis C Action Plan, however, 
that additional resources were allocated to develop HCV services: £2 million during 
Phase I and £37 million during Phase II. One of the key aims of the Action Plan was 
to identify undiagnosed infections. During Phase I, NHS Boards considered ways of 
improving accessibility of testing services, and to identify and offer HCV testing to at 
risk groups.[5] Phase II included awareness raising activities – targeted at 
professionals, particularly general practitioners, and at risk individuals – to promote 
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HCV testing.[6]  Minimally invasive dried blood spot (DBS) sampling was also 
introduced during Phase II in community drug services to increase access of testing. 
In Scotland, DBS antibody testing is undertaken using a modified ORTHO HCV 
version 3.0 ELISA kit with close to 100% sensitivity and 100% specificity. [7, 8] To 
monitor the performance of these actions Health Protection Scotland (HPS) 
established surveillance of HCV testing in Scotland. We utilise these data to examine 
i) trends in HCV testing in Scotland and ii) whether there has been an increase in 
people being tested for, and diagnosed with, HCV in Scotland following the launch of 




The West of Scotland Specialist Virology Centre (WoSSVC); East of Scotland 
Specialist Virology Centre (EoSSVC); Department of Medical Microbiology at 
Aberdeen Royal Infirmary and Ninewells Hospital & Medical School provided HPS 
with retrospective data on all anti-HCV tests undertaken between January 1999 and 
December 2011. Almost three-quarters of new HCV diagnoses in Scotland are 
reported from the NHS boards served by these laboratories.[9]  
Data provided includes: forename, surname, sex, date of birth; either 
Community Health Index (CHI) number, hospital/clinic number, or genitourinary 
medicine (GUM) clinic number; requesting clinician information (address and health 
board); and test information (specimen date and anti-HCV result).  
 
Preparation of data  
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As a standardised request form is not used for HCV testing, risk information is 
available only when volunteered at the time of the test request. Free-text, clinical 
details fields were searched for mention of PWID risk. Ethnicity (categorised as 
“South Asian” or “Other”) was determined using the name recognition software, Nam 
Pehchan.[10] A soundex code, generated using the surname, and the forename initial 
were retained; full names were excluded from the dataset for the subsequent analysis. 
Approval for data collection and analysis was given by the Clinical Governance 
Committee at Health Protection Scotland.  
 Tests of children aged less than two years old were excluded as these may 
indicate the presence of passively-acquired maternal antibodies rather than true 
infection. [11] Tests requested in occupational health, fertility clinics, renal units, and 
confirmatory tests were excluded. Positive results were laboratory confirmed and 
unconfirmed or equivocal results were also excluded. 
Test results belonging to the same individual were matched deterministically 
using one of four criteria: (i) sex, date of birth, forename initial and surname soundex; 
(ii) CHI number; (iii) sex, date of birth, and hospital/clinic number and (iv) source of 
request and GUM number for tests requested in the GUM setting. Almost all (97%) 
test records had sufficient data to match on at least one of these criteria.  
Derived fields were calculated: anti-HCV results were recoded “positive” or 
“negative”; age at the time of test was generated using date of birth and date of test 
and categorised into eight age groups. Setting was determined using the address of 






Segmented regression analysis was used to evaluate the effect of Scotland’s 
HCV Action Plan on the number of a) anti-HCV tests and b) anti-HCV positive 
tests.[12] The data were split into 6 monthly intervals and categorised as pre-Action 
Plan (January 1999 to December 2006) or Action Plan (January 2007 to December 
2011). The Action Plan was launched in late 2006 so January 2007 is used as the 
change point. Pre–Action Plan trends are compared to Action Plan trends and the 
level change in anti-HCV testing, at the change, is estimated. Negative binomial 
models were fitted to account for overdispersion in the data.[12, 13]  
The model takes the form: 
log(Yt) = β0 + β1 
*
 Timet + β2 * APt + β3 
*
 TimeAPt + et     
where Yt is the mean number of tests per 6 monthly interval t; Time counts the 
number of intervals t since the beginning of  observation ; AP is an indicator variable 
(0 before the change point and 1 after); TimeAP counts the number of intervals t 
during the Action Plan segment; β0 is the baseline number of tests at the start of 
observation ; β1 describes the trend in testing pre- Action Plan; β2 estimates the level 
change in the number of tests; β3 estimates the change in trend in testing during the 
Action Plan compared with the trend pre- Action Plan; et is the model error term. The 
trend in testing during the Action Plan is calculated as β1 + β3. A second model 
comparing the trends before and after the introduction of DBS testing in 2009, for all 
tests and those from drug services was analysed. Results are presented in the form of 
rate ratios (RR) with 95% confidence intervals and associated p-values. 
 
RESULTS 
Overall trends in, and characteristics of, those tested 
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The annual number of people tested for anti-HCV increased from 15,515 in 
1999 to 30,906 in 2011 (Figure 1), representing a total of 297,689 tests. Among those 
tested, 9% (27,966) tested anti-HCV positive, 55% (164,147) were male, 60% 
(177,665) aged 20-49 years at the time of their first test, 49% (145,140) and 32% 
(93,954) were first tested in the hospital and general practice settings, respectively 
 (Table 1). Three percent (9332) were of South Asian ethnicity. Injecting drug use was 
reported with 9% (25,580) of all anti-HCV tests, and 34% of positive anti-HCV tests 
(indicating considerable under-reporting as more than 80% of positive tests would be 
expected to be attributed to injecting drug use).[14] Between the Pre-Action and 
Action Plan periods, the average annual number of tests increased (from 19,058 to 
29,045), average annual number of positive tests increased (from 1993 to 2405) and 
average positivity decreased (from 10.5% to 8.3%).  The average annual percentage 
change in the number of people tested was 5.1% during the Pre-Action Plan period 
and 6.1% during the Action Plan period while the respective average annual 
percentage change in the number of positives detected was -2.9% and 13.4%.  
New HCV diagnoses decreased from 1,483 in 1999 to 1,055 in 2006. This 
trend reversed and increased annually to a peak of 1,967 in 2011. Following very few 
diagnoses in drug services prior to 2009, this setting accounted for 12.7% of 
diagnoses in 2009, 24.3% of diagnoses in 2010 and 20.6% in 2011.   
 
Trends in testing, and testing positive, by setting  
Figure 2 shows the annual number of people tested and the annual number 
tested positive.  Testing in hospitals remained largely stable, and consequently the 
proportion testing in this setting decreased over time: from 66% (10,254) in 1999 to 
41% (12, 767) in 2011. In drug services, where DBS testing was introduced in 2009, 
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there was a six-fold increase in the annual number of people tested from 488 in 2008 
to a peak of 1,706 in 2010 followed by a decline to 1,473 in 2011. In the prison 
setting, there was also an increase from 288 in 2008 to 571 in 2010 and this level was 
maintained in 2011.  
In general practice testing increased steadily, more than trebling from 3,336 in 
1999 to 11,453 in 2011, while the number of positive tests increased at a lower rate 
(rising 1.5-1.7 fold, from 422 in 1999 to a peak of 728 in 2011). In NHS Lothian, 
however, there was a four-fold increase from 66 positives in 1999 to 260 in 2011. The 
number of general practices testing increased marginally from 502 requesting tests in 
1999 to 538 requesting tests in 2011, accounting for almost all of the practices in 




Table 1: Characteristics of the annual number of people being tested for anti-HCV, and the number who tested positive, during 1999-2011, stratified by pre-Action 
Plan (1999-2006) and Action Plan (2007-2011) periods 
 
    1999-2011 Pre-Action Plan (1999-2006) Action Plan (2007-2011) 









Characteristic   N % n % (of N) N % n % (of N) N % n % (of N) 
All   297689 - 27966 9.4% 19058 - 1993 10.5% 29045 - 2405 8.3% 
Gender Female 130337 43.8% 9325 7.2% 8465 44.4% 678 8.0% 12524 43.1% 780 6.2% 
  Male 164147 55.1% 18395 11.2% 10422 54.7% 1299 12.5% 16154 55.6% 1601 9.9% 
  Not Reported 3205 1.1% 246 7.7% 17 0.1% 16 94.1% 366 1.3% 24 6.6% 
Age at first test <20 20613 6.9% 743 3.6% 1432 7.5% 70 4.9% 1831 6.3% 36 2.0% 
  20-29 61932 20.8% 6828 11.0% 3954 20.7% 588 14.9% 6061 20.9% 424 7.0% 
  30-39 65590 22.0% 11050 16.8% 4145 21.7% 798 19.3% 6484 22.3% 933 14.4% 
  40-49 50143 16.8% 6265 12.5% 2987 15.7% 334 11.2% 5249 18.1% 719 13.7% 
  50-59 38461 12.9% 1979 5.1% 2423 12.7% 108 4.5% 3815 13.1% 224 5.9% 
  60+ 58514 19.7% 689 1.2% 3845 20.2% 48 1.2% 5551 19.1% 61 1.1% 
  NK 2436 0.8% 412 16.9% 271 1.4% 47 17.3% 53 0.2% 8 15.1% 
Setting Hospital 145140 48.8% 13118 9.0% 10536 55.3% 1043 9.9% 12170 41.9% 956 7.9% 
  GP 93954 31.6% 7632 8.1% 5421 28.4% 523 9.6% 10117 34.8% 690 6.8% 
  Drug Service 5399 1.8% 1959 36.3% 67 0.4% 13 19.4% 973 3.3% 371 38.1% 
  Prison 4200 1.4% 1490 35.5% 257 1.3% 114 44.4% 429 1.5% 116 27.0% 
  GUM Clinic 33677 11.3% 1398 4.2% 1699 8.9% 88 5.2% 4018 13.8% 139 3.5% 
  Other/Not Known 15319 5.1% 2369 15.5% 1079 5.7% 212 19.6% 1338 4.6% 135 10.1% 
NHS Board 
Greater Glasgow & 
Clyde 119786 40.2% 16945 14.1% 8257 43.3% 1242 15.0% 10746 37.0% 1402 13.0% 
  Lothian 85571 28.7% 4215 4.9% 4869 25.5% 231 4.7% 9323 32.1% 473 5.1% 
  Grampian 55243 18.6% 4676 8.5% 3761 19.7% 379 10.1% 5031 17.3% 329 6.5% 
  Tayside 37089 12.5% 2130 5.7% 2171 11.4% 140 6.4% 3944 13.6% 201 5.1% 
Ethnicity South Asian 9332 3.1% 1048 11.2% 423 2.2% 57 13.5% 1190 4.1% 119 10.0% 
  Other 288357 96.9% 26918 9.3% 18636 97.8% 1936 10.4% 27854 95.9% 2286 8.2% 
Risk PWID Reported 25580 8.6% 9362 36.6% 1702 8.9% 599 35.2% 2392 8.2% 914 38.2% 
  Not Reported 272109 91.4% 18604 6.8% 17356 91.1% 1393 8.0% 26652 91.8% 1492 5.6% 
  
Average Annual Percentage Change 
Trend in Testing* Percentage change 6.4% 2.3% 5.1% -2.9% 6.1% 13.4% 
 
95% CI 6.3 to 6.5 2.0 to 2.6 4.8 to 5.3 -3.5 to -2.2 5.7 to 6.5 12.0 to 14.9 





Trends in testing associated with the Action Plan: Segmented regression  
Results of the segmented negative binomial regression analysis are shown in 
Table 2, with associated graphs in appendices 2 and 3. In the Pre-Action Plan period, 
the overall trend in the number of tests was significantly increasing (RR=1.03 per 6-
month period). This was reflected across GP, drug services and GUM clinics; in 
prisons there was a decreasing trend (RR=0.94) and no significant change in trend 
was observed in the hospital setting. There was a significant increase overall in level 
change in outcomes (i.e. the number of tests) at the start of the Action Plan period 
(RR=1.09) with only the GUM and prisons showing a significant level change in the 
number of tests (RR=1.42 and RR=1.32, respectively). Overall, there was no 
significant change in the trend in testing during the Action Plan period, compared to 
the pre-Action period. However, there was a significantly increasing trend in testing 
during the Action Plan, compared to pre-Action Plan period within prison (RR=1.19), 
drug services (RR=1.11), and hospital (RR=1.01); while there were significantly 
reduced trends within GP (RR=0.98) and GUM clinics (RR=0.87).   
 
Trends in testing positive associated with the Action Plan: Segmented regression 
In the Pre-Action Plan period, the trend in positive tests was significantly decreasing 
overall (RR=0.98) and across most settings, with the exception of an increasing trend 
in GP (RR=1.03) and drug services (RR=1.10); although the numbers in this latter 
setting were low. Only in the GUM setting was there a significant level change in the 
number of positive tests at the start of the Action Plan (RR=1.76). The change in trend 
between the two periods was significantly increased in all settings except general 
practice, and had increased the most in drug services (RR=1.43).  
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Table 2: Results of negative binomial segmented regression analysis to identify 1) effect of HCV action plan on testing outcomes by setting and 2) the introduction of 
dried blood spot testing on testing outcomes; between 1999 and 2011  
 
    Initial Trend Level Change in Outcomes Change in trend Post Trend 
    RR (95% CI) p value RR (95% CI) p value RR (95% CI) p value RR (95% CI) 
Model 1    Pre-Action 1996-2006  Start of Action Plan  Change in Trend* Action Plan 2007-2011 
a) Annual Number of 
People Tested               
  All Settings 1.025 (1.020-1.030) <0.001 1.092 (1.016-1.174) 0.016 1.003 (0.993-1.014) 0.558 1.028 (1.012-1.044) 
  
General 
Practice 1.059 (1.053-1.065) <0.001 1.023 (0.939-1.115) 0.596 0.979 (0.967-0.991) 0.001 1.037 (1.018-1.056) 
  Drug Services 1.146 (1.100-1.197) <0.001 1.472 (0.817-2.654) 0.198 1.108 (1.016-1.209) 0.021 1.270 (1.115-1.446) 
  Prison 0.943 (0.927-0.961) <0.001 1.320 (1.004-1.736) 0.047 1.191 (1.146-1.239) <0.001 1.124 (1.062-1.190) 
  GUM Clinic 1.115 (1.101-1.130) <0.001 1.420 (1.167-1.727) <0.001 0.870 (0.845-0.895) <0.001 0.970 (0.930-1.012) 
  Hospital 1.004 (0.999-1.010) 0.127 1.021 (0.937-1.112) 0.637 1.014 (1.001-1.027) 0.03 1.018 (1.000-1.037) 
b) Annual number of 
people tested positive               
  All Settings 0.981 (0.970-0.992) 0.001 0.888 (0.747-1.056) 0.18 1.102 (1.075-1.131) <0.001 1.081 (1.042-1.122) 
  
General 
Practice 1.033 (1.024-1.043) <0.001 0.987 (0.861-1.132) 0.856 0.987 (0.967-1.007) 0.188 1.020 (0.990-1.050) 
  Drug Services 1.101 (1.025-1.182) 0.008 0.711 (0.273-1.849) 0.484 1.432 (1.246-1.646) <0.001 1.577 (1.277-1.946) 
  Prison 0.920 (0.897-0.943) <0.001 1.014 (0.681-1.511) 0.944 1.228 (1.161-1.299) <0.001 1.130 (1.042-1.225) 
  GUM Clinic 0.973 (0.953-0.994) 0.011 1.761 (1.304-2.379) <0.001 1.054 (1.011-1.100) 0.016 1.025 (0.962-1.093) 
  Hospital 0.971 (0.956-0.987) <0.001 0.857 (0.668-1.101) 0.228 1.076 (1.037-1.116) <0.001 1.045 (0.991-1.102) 
Model 2    Pre-DBS 1999-2009 Introduction of DBS Testing  Change in Trend
†
 DBS Period 2009-2011 
c) Annual Number of 
People Tested               
  All Settings 1.030 (1.027-1.034) <0.001 1.118 (1.009-1.223) 0.034 0.970 (0.942-0.999) 0.042 1.000 (0.968-1.033) 
  Drug Services 1.184 (1.154-1.215) <0.001 3.445 (1.1748-6.787) <0.001 0.840 (0.695-1.016) 0.072 0.995 (0.802-1.234) 
d) Annual number of 
people tested positive               
  All Settings 0.989 (0.981-0.996) 0.003 1.670 (1.322-2.111) <0.001 1.014 (0.950-1.083) 0.671 1.003 (0.932-1.079) 
  Drug Services 1.139 (1.103-1.176) <0.001 12.050 (6.350-22.904) <0.001 0.862 (0.725-1.027) 0.096 0.982 (0.799-1.208) 
                  
*Change in trend in the Action Plan Period (2007-2011), compared to Pre-Action Plan period         




Trends associated with the introduction of DBS testing: Segmented regression  
The second model, examining the introduction of DBS testing, found an increasing 
pre-intervention trend in testing in drug services (RR=1.18) with a significant three-fold 
increase in testing during 2009 (RR=3.45). Prior to DBS testing, the trend in positive tests 
was similarly increasing in drug services (RR=1.14) but the level change in the number of 
positive tests during 2009 was greater, with a twelve-fold increase. Following the 
introduction of DBS testing, there were no significant trends although there were a limited 
number of data points following the change point in this model.  
 
DISCUSSION 
This is the first study to examine HCV testing practice in the context of a major 
government policy and investment. The Hepatitis C Action Plan for Scotland has been 
described as an example of best practice in the Global Commission on Drug Policy 2013 
report “The Hidden Hepatitis C Epidemic”.[15] A key aim was to identify undiagnosed 
infections and through increases in testing and diagnoses observed, the proportion 
undiagnosed reduced from 62% in 2006 to 45% in 2013. [1, 6] As a result, Scotland is now 
among a small number of countries where the majority of hepatitis C infected people have 
been diagnosed.[16] 
The greatest impact was through introduction of Dried Blood Spot (DBS) testing in 
community drug services. Given previously negligible levels of diagnosis in this setting, the 
significant increase in testing described can be attributed to DBS testing. This has driven the 
overall increases in new diagnoses observed since 2009, with drug services now referring 
approximately 20% of new diagnoses each year compared with <1% before the introduction 
of DBS testing.[9] In a randomised controlled cluster study in specialist drug clinics and 
prisons in England and Wales during 2004, services utilising DBS testing undertook 14.5% 
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more HCV testing than those employing standard testing methods.[17]  Following 
introduction of DBS testing at substance misuse services in Wales, a six-fold increase in 
testing was also observed. [18] DBS testing overcomes the need for a venous blood sample, a 
known barrier to testing among PWID due to damaged veins, and requirement of a clinician 
to take the sample. Therefore availability of testing to those at the greatest risk of infection, 
who may not see a GP but are attending harm reduction or other drug services is 
increased.[17-19]  
DBS screening for HCV in drug services has previously been estimated to be cost-
effective within standard UK willingness-to-pay thresholds while in prisons it is cost 
effective when antiviral treatment is completed in at least 40% of cases.[20]  
McDonald et al. found variation between diagnosis setting and attendance at specialist 
liver clinics; with 60% of those diagnosed in general practice attending within twelve months 
compared with 40% among those diagnosed through drug services.[21] This may indicate a 
more established patient pathway, allowing patients to be referred to specialist care by their 
GP, or differences among individuals diagnosed in different settings.  
Testing and case-finding for HCV in general practice, therefore, remains important 
and was a major focus of both the Action Plan and pre-Action Plan initiatives, as previously 
discussed. Based solely on analysis of the testing data we have found no evidence of an 
impact. Testing in primary care increased throughout the observation period but during the 
Action Plan did so at a lower level and new diagnoses remained largely stable, suggesting 
GPs are testing more patients who are at low risk of infection.[9] 
A 2007 needs assessment found that 80% of GPs reported not routinely asking 
patients about risk factors for HCV.[6] More recently, a mixed methods analysis of HCV case 
finding in England identified similar barriers with GPs reporting confidence in their 
knowledge of HCV but remembering to offer a test was an issue. They suggested IT systems 
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be improved to prompt GPs to offer a test to at risk patients.[22] However, a study of HCV 
screening in general practice found several reasons why patients may decline a test when 
offered; including not recognising risk and poor venous access.[23] Only in NHS Lothian, 
where many drug services are delivered through general practice, was an increase in positive 
tests and diagnoses in recent years found.  
Identifying undiagnosed HCV-infected individuals remains a key issue. Most 
screening strategies rely on a targeted approach based on the ascertainment of risk factors.[4, 
23- 26] Recently the Centres for Disease Control (CDC), citing the limitations of this 
approach, have recommended birth cohort screening in the United States for those born 
during 1945-1965.[27] Here, we have demonstrated that offering HCV testing in services 
designed for those at the highest risk, i.e. drug services, can be valuable for case-finding.  
However, following a peak in testing in 2010, there was a decrease in 2011. . There are 
approximately 3,000 new clients attending drug services in four largest NHS boards per year 
who report a history of injecting.[28] This represents a maximum threshold of coverage in 
this setting, while only 49% of PWID interviewed at services providing injection equipment 
in 2011 reported being tested for HCV in the last year.[1] Expansion of DBS testing settings 
may increase coverage and settings where PWID can be identified, such as pharmacies 
dispensing methadone, could be considered.  
It has been established that identification of former PWID can be made in general 
practice, particularly in practices of high social deprivation, and that the offer of HCV testing 
is generally accepted in this group.[23, 24] The availability of DBS testing in primary care, 
therefore, may overcome barriers such as poor venous access and this should also be 
considered.[22] A combination of DBS testing for PWID engaging with drug services and 
improved targeted case finding of former PWID by GPs may be preferable to adopting a birth 
cohort screening approach..  
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Segmented regression has been used to examine the impact of a wide variety of real 
world events such as policy changes, public health initiatives or environmental exposure.[29- 
31] The main strength of this methodology is that it has been possible to examine changes in 
testing activity prior to, at the time of and following the launch of the Action Plan and the 
introduction of DBS testing.  
There are a number of limitations to a study of this nature. In particular, identification 
of duplicate tests for an individual using electronic matching and limited identifiers. Four 
matching criteria were employed to try to ensure duplicate tests were identified. Due to lack 
of risk information it has not been possible to describe, or analyse, testing among 
recommended groups.[2- 4] Aside from national initiatives described in Appendix 1, there 
have also been local initiatives, perhaps at NHS board or service level; increased press 
attention and additions to the scientific literature in this field. It is consequently difficult to 
evaluate a discrete intervention using testing data alone.  
Despite these limitations, this study highlights the impact of a National Action Plan 
on testing and case-finding of HCV. While previous initiatives focused almost exclusively on 
testing by GPs, new approaches in the form of DBS testing by other community setting 
practitioners have resulted in an increase in testing and diagnoses at the national level that 
have not been elsewhere demonstrated. These findings can be used, and improved on, by 




WHAT IS ALREADY KNOWN ON THIS SUBJECT? 
 In most resource rich countries, the majority of chronic hepatitis C infections remain 
undiagnosed; this is a key challenge in the control and management of the epidemic 
 
 Barriers to testing have been previously ascertained. Among patients these include 
poor awareness of the disease, fear of stigma or treatment and not engaging with 
health service. Among professionals barriers include lack of time for consultations, 
not routinely ascertaining risk activities and poor venous access. 
 
 
WHAT THIS STUDY ADDS? 
 
 Dried blood spot sampling in community drug services improves hepatitis C case 
finding in those at risk of infection by overcoming the established barriers to testing 
such as poor veins or limited contact with health services.  
 
 No evidence of an impact of awareness raising activities in GPs was found although 
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Figure 1: Annual number of people (a) tested for anti-HCV and (b) newly diagnosed with 
anti- HCV in Scotland’s four largest health boards during 1999-2011, by setting.  
 
Figure 2: Annual number of people tested for anti-HCV and number tested positive in 
Scotland’s four largest health boards by setting, 1999-2011 
 
Table 1: Characteristics of the annual number of people being tested for anti-HCV, and the 
number who tested positive, during 1999-2011, stratified by pre-Action Plan (1999-2006) and 
Action Plan (2007-2011) periods 
 
Table 2: Results of negative binomial segmented regression analysis to identify 1) effect of 
HCV action plan on testing outcomes by setting and 2) the introduction of dried blood spot 
testing on testing outcomes; between 1999 and 2011 
 
